Pubblicazioni per linea Response

15 09, 2015

Matteo Landriscina et al., RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study. Oncology Letters

Diatech Pharmacogenetics2017-08-08T12:29:23+02:00

15 09, 2015

Valentina Guarneri et al., Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. The Oncologist

Diatech Pharmacogenetics2017-08-08T09:48:41+02:00

15 09, 2015

Maria Orsaria et al., HPV-related Oropharyngeal Squamous Cell Carcinoma: p16INK4A Immunohistochemistry or HPV Genotyping? Anticancer Research

Diatech Pharmacogenetics2017-08-08T09:44:43+02:00

1 08, 2015

Cangi MG, Biavasco R, Cavalli G, et al BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease Annals of the Rheumatic Diseases 2015;74:1596-1602.

Diatech Pharmacogenetics2017-08-08T10:18:40+02:00

28 07, 2015

Veronica Villani, Beatrice Casini, Andrea Pace, et al., “The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma,” Disease Markers, vol. 2015, Article ID 604719, 6 pages, 2015. doi:10.1155/2015/604719

Diatech Pharmacogenetics2017-08-08T15:08:04+02:00

9 06, 2015

Marta Schirippa et al., BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. British Journal of Cancer

Diatech Pharmacogenetics2017-08-08T12:26:30+02:00

8 06, 2015

Hauck, F., Oliveira-Silva, M., Dreyer, J.H. et al. Prevalence of HPV infection in head and neck carcinomas shows geographical variability: a comparative study from Brazil and Germany. Virchows Arch (2015) 466: 685.

Diatech Pharmacogenetics2017-08-08T11:20:45+02:00

8 06, 2015

Lo Dico, A., Martelli, C., Valtorta, S. et al. Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model. Eur J Nucl Med Mol Imaging (2015) 42: 1093.

Diatech Pharmacogenetics2017-08-08T11:24:45+02:00

7 05, 2015

Corrado Iaccarino et al., Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. Clinical Neurology and Neurosurgery

Diatech Pharmacogenetics2017-08-08T11:43:22+02:00

7 05, 2015

Riccardo Giampieri et al., Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine

Diatech Pharmacogenetics2017-08-08T12:25:05+02:00

Precedente 8910 Successivo